Mailing Lists

Rabbit IgG for Influenza A/B

Generation of the highly effective antibodies against the natural viral proteins is essential for research and development of vaccines and immune therapeutics as well as for in vitro diagnostics.

In conventional antibody production, the antibodies are raised against purified viral proteins, thus have limitations on the specificity, for the purified viral proteins may not be identical to the natural antigenic viral proteins due to the lack of correct folding and post translational modification such as glycosylation. 

eEnzyme uses an improved genetic immunization technique to raise the high titers of rabbit polyclonal antibodies against the natural antigenic viral proteins. This technology is based on delivering an expression plasmid encoding the protein of interest into an animal. The animal’s cells are directly transfected with the plasmid where they use it to produce the protein. The low level consistent expression of the immunogenic viral protein in vivo guarantees the reproducible productions of specific high-affinity antibodies, and these antibodies are superior in recognizing the native viral proteins.

Selected Citation:
Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice. PLoS One 13, e0193680 (2018). 
In this research, many of our subtype specific polyclonal antibodies were used.

Displaying products 1 - 25 of 50 results
Page 1 of 2 Page 12movenext
Anti-HA1 (A/California/07/2009) (H1N1)
Anti-H7 (A/Shanghai/2/2013) (H7N9)
Anti-H3 (Influenza A/Wyoming/3/03) (H3N2)
Anti-H1 (Influenza A/South Carolina/1/18) (H1N1)
Anti-H1 (A/Ohio/Swine/01/07) (H1N1)
Anti-H1 (Influenza A/Brisbane/59/07) (H1N1)
Anti-H3 (Influenza A/Brisbane/10/07) (H3N2)
Anti-H16 (Influenza A/Sweden/99) (H16N3)
Anti-H14 (Influenza A/mallard/Gurjev/263/1982)
Page 1 of 2 Page 12movenext